Logo image of LXRX

LEXICON PHARMACEUTICALS INC (LXRX) Stock Overview

NASDAQ:LXRX - US5288723027 - Common Stock

1.1 USD
-0.05 (-4.35%)
Last: 8/29/2025, 8:00:00 PM
1.11 USD
+0.01 (+0.91%)
After Hours: 8/29/2025, 8:00:00 PM

LXRX Key Statistics, Chart & Performance

Key Statistics
52 Week High2.17
52 Week Low0.28
Market Cap399.74M
Shares363.40M
Float358.94M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.33
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10/bmo
IPO04-07 2000-04-07
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


LXRX short term performance overview.The bars show the price performance of LXRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

LXRX long term performance overview.The bars show the price performance of LXRX in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of LXRX is 1.1 USD. In the past month the price increased by 2.8%. In the past year, price decreased by -36.42%.

LEXICON PHARMACEUTICALS INC / LXRX Daily stock chart

LXRX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About LXRX

Company Profile

LXRX logo image Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 103 full-time employees. The company went IPO on 2000-04-07. The company is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The company has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. The company is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. The company is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.

Company Info

LEXICON PHARMACEUTICALS INC

2445 Technology Forest Blvd, 11Th Floor

The Woodlands TEXAS 77381 US

CEO: Lonnel Coats

Employees: 103

LXRX Company Website

LXRX Investor Relations

Phone: 12818633000

LEXICON PHARMACEUTICALS INC / LXRX FAQ

What is the stock price of LEXICON PHARMACEUTICALS INC today?

The current stock price of LXRX is 1.1 USD. The price decreased by -4.35% in the last trading session.


What is the ticker symbol for LEXICON PHARMACEUTICALS INC stock?

The exchange symbol of LEXICON PHARMACEUTICALS INC is LXRX and it is listed on the Nasdaq exchange.


On which exchange is LXRX stock listed?

LXRX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for LEXICON PHARMACEUTICALS INC stock?

11 analysts have analysed LXRX and the average price target is 2.81 USD. This implies a price increase of 155% is expected in the next year compared to the current price of 1.1. Check the LEXICON PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is LEXICON PHARMACEUTICALS INC worth?

LEXICON PHARMACEUTICALS INC (LXRX) has a market capitalization of 399.74M USD. This makes LXRX a Small Cap stock.


How many employees does LEXICON PHARMACEUTICALS INC have?

LEXICON PHARMACEUTICALS INC (LXRX) currently has 103 employees.


What are the support and resistance levels for LEXICON PHARMACEUTICALS INC (LXRX) stock?

LEXICON PHARMACEUTICALS INC (LXRX) has a support level at 1.07 and a resistance level at 1.19. Check the full technical report for a detailed analysis of LXRX support and resistance levels.


Is LEXICON PHARMACEUTICALS INC (LXRX) expected to grow?

The Revenue of LEXICON PHARMACEUTICALS INC (LXRX) is expected to grow by 153.81% in the next year. Check the estimates tab for more information on the LXRX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy LEXICON PHARMACEUTICALS INC (LXRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LEXICON PHARMACEUTICALS INC (LXRX) stock pay dividends?

LXRX does not pay a dividend.


When does LEXICON PHARMACEUTICALS INC (LXRX) report earnings?

LEXICON PHARMACEUTICALS INC (LXRX) will report earnings on 2025-11-10, before the market open.


What is the Price/Earnings (PE) ratio of LEXICON PHARMACEUTICALS INC (LXRX)?

LEXICON PHARMACEUTICALS INC (LXRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.33).


What is the Short Interest ratio of LEXICON PHARMACEUTICALS INC (LXRX) stock?

The outstanding short interest for LEXICON PHARMACEUTICALS INC (LXRX) is 7.54% of its float. Check the ownership tab for more information on the LXRX short interest.


LXRX Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to LXRX. When comparing the yearly performance of all stocks, LXRX is one of the better performing stocks in the market, outperforming 79.92% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LXRX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to LXRX. LXRX has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LXRX Financial Highlights

Over the last trailing twelve months LXRX reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS increased by 57.69% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -53.47%
ROE -93.19%
Debt/Equity 0.43
Chartmill High Growth Momentum
EPS Q2Q%105.88%
Sales Q2Q%1652.64%
EPS 1Y (TTM)57.69%
Revenue 1Y (TTM)1488.26%

LXRX Forecast & Estimates

11 analysts have analysed LXRX and the average price target is 2.81 USD. This implies a price increase of 155% is expected in the next year compared to the current price of 1.1.

For the next year, analysts expect an EPS growth of 62.83% and a revenue growth 153.81% for LXRX


Analysts
Analysts80
Price Target2.81 (155.45%)
EPS Next Y62.83%
Revenue Next Year153.81%

LXRX Ownership

Ownership
Inst Owners76.48%
Ins Owners0.86%
Short Float %7.54%
Short Ratio6.8